MLN120B

MLN120B (ML120B) is a potent, ATP competitive, and orally active inhibitor of IKKβ with an IC50 of 60 nM. MLN120B inhibits multiple myeloma cell growth in vitro and in vivo and also can be used for the research of rheumatoid arthritis[1][2].

Product Specifications

CAS Number

[783348-36-7]

Product Name Alternative

ML120B

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IKK

Type

Reference compound

Related Pathways

NF-κB

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MLN120B.html

Purity

99.76

Solubility

DMSO : ≥ 31 mg/mL

Smiles

O=C(C1=CC=CN=C1C)NC2=C(OC)C(Cl)=CC3=C2NC4=C3C=CN=C4

Molecular Formula

C19H15ClN4O2

Molecular Weight

366.80

Precautions

H302, H315, H319, H335

References & Citations

[1]Hideshima T, et all. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 1;12 (19) :5887-94.|[2]Schopf L, et al. IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum. 2006 Oct;54 (10) :3163-73.|[3]Ansaldi D, et al. Imaging pulmonary NF-kappaB activation and therapeutic effects of MLN120B and TDZD-8. PLoS One. 2011;6 (9) :e25093.|[4]Nagashima K, et al. Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta. Blood. 2006 Jun 1;107 (11) :4266-73.